Berkshire Biomedical, a medical equipment manufacturer based in Dallas, announced that it had acquired third-party funding totaling $3 million, which the company will use to advance the development of its prescription-drug and virtual-care management system. The system uses dual biometric authentication, which includes dental recognition.
The biometric system is currently not available for commercial use but will be used to curb nonadherence to medication. The company states that medication nonadherence causes roughly 125,000 deaths in America each year and makes up nearly 10% of hospitalizations.
The system’s main product is COPA, a computerized oral prescription administrator. COPA will help improve the results of customer-specific virtual medicine delivery through the use of data and technology. The system ensures that a specific individual receives a particular dosage of medication prescribed for them, through the help of biometric authentication.
Dallas Innovates notes that COPA has not only proven to be effective in handling e-prescribing formats and workflows but has also been found to be advantageous in various ways for pharmacists, patients and physicians. The system was tested and proven to be efficient as well.
The company explains that to operate the product, a mobile-powered handheld device, which allows the transmission of practical dosing parameter information in actual time, will be used. This will assist health-care personnel in managing different patients’ therapeutic regimen.
The company’s report also highlights that the device will be linked to a cloud storage platform, which allows patients to use dentition and fingerprint recognition, ensuring that drug, security and safety measures are adhered to.
Berkshire Biomedical chairman and founder Thomas Rouse stated that the new financing that the company had secured was a good opportunity for its market growth. He explained that the funds would be invested in various ways that would help commercialize its product, which is currently being reviewed by the U.S. Food and Drug Administration (“FDA”).
In a statement, Rouse added that the company was also looking for and entering collaborations with a few strategic partners this year, in preparation for market clearance by the FDA. He noted that the company’s objective was to initiate partnerships with top-tier investors and partners that would adopt digital therapeutic solutions and critical virtual care in the rapidly evolving healthcare ecosystem.
Prior to securing the $3 million in funding from third-party investors, the founders of Berkshire Biomedical are said to have financed the company’s product development and operations entirely.
Meanwhile United Medical Equipment Business Solutions Network Inc. has carved out a niche for itself as the go-to firm for technology, information and equipment needed to ensure the health and safety of veterans, seniors and medical workers.
NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment Business Solutions Network Inc. are available in the company’s newsroom at https://ibn.fm/UnitedMed
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Cancer statistics underscore the urgency of ongoing cancer research and the need for more effective…
A team of researchers has leveraged a technique called temporal learning to train an AI…
Sheridan was recently named as a finalist for the 2025 EY Entrepreneur of the Year…
“Research on the treatment of cancer is fundamental to improving outcomes for all patients affected…
Adageis offers an AI-powered financial technology platform tailored to healthcare providers seeking a financially positive…
A new study focusing on twins has found that individuals with a larger presence of…